Patent · US Active

Concentration-dependent self-interaction assay

US11428695B2 · kind B2 · utility

0Cited by

5References

18Claims

0Family size

Assignee

REGENERON PHARMACEUTICALS, INC. · US

Inventors

Michael Marlow · Greenwich, US
Michael Sennett · Somerville, US
Michael Schneider · Wien, AT

Key dates

Filing date	Aug 18, 2017
Grant date	Aug 30, 2022
Priority date	—
Expiry date	Aug 18, 2037

Classification

Technology area (CPC G)Physics
CPC primaryG01N33/587
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Methods for producing high concentration protein formulations having high stability are provided. Assays for selecting proteins and formulation conditions that have high self-repulsive attributes are used as an early step in the manufacturing process. Specifically, a protein concentration-dependent self-interaction nanoparticle spectroscopy method is employed as a protein colloidal interaction assay.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.